Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 13/20 | 0.54 |
| ▸ | CA1 | P00915 | 13/20 | 0.54 |
| ▸ | CA2 | P00918 | 13/20 | 0.54 |
| ▸ | CA9 | Q16790 | 13/20 | 0.54 |
| ▸ | FYN | P06241 | 5/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.45 |
| ▸ | CA3 | P07451 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA6 | P23280 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1943789 | 0.89 | CA2 (0.69) | CA12CA1CA2CA9FYN | |
| SCHEMBL1946953 | 0.88 | CA1 (0.55) | CA12CA1CA2CA9FYN | |
| SCHEMBL1943668 | 0.85 | FYN (0.46) | CA12CA1CA2CA9FYN | |
| SCHEMBL1946905 | 0.84 | CA1 (0.55) | CA12CA1CA2CA9FYN | |
| SCHEMBL15603268 | 0.84 | CA1 (0.54) | CA12CA1CA2CA9FYN | |
| SCHEMBL1944265 | 0.83 | CA1 (0.55) | CA12CA1CA2CA9FYN | |
| SCHEMBL1948011 | 0.82 | CA12 (0.53) | CA12CA1CA2CA9FYN | |
| SCHEMBL1946803 | 0.82 | FYN (0.68) | CA12CA1CA2CA9FYN | |
| SCHEMBL1652931 | 0.81 | FYN (0.58) | CA12CA1CA2CA9FYN | |
| SCHEMBL1945593 | 0.81 | FYN (0.69) | CA12CA1CA2CA9FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | claimed |
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | TGFBR1, TGFBR2, IGF1R | CA12 4385/4885CA1 4158/4885CA2 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.